Drug Trial Radar · NCT01838551
Treatment for Endogenous Cushing's Syndrome
Last checked: Nov 20, 2026Latest source record: Apr 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
94
Actual
Start
Aug 2014
Primary completion
Apr 2018
Study completion Nov 2018
Sponsor
- Lead sponsor
- Cortendo ABIndustry
- Sponsor type
- Industry
- First posted
- Apr 24, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to evaluate the clinical responder rate, defined as the proportion of subjects with normal UFC after 6 months of treatment with COR-003 in the Maintenance Phase without dose increase, and to evaluate the range of effective doses in subjects with various levels of hypercortisolism.
Conditions
- Endogenous Cushing's Syndrome
Interventions
LevoketoconazoleDrug
Levoketoconazole is the 2S,4R- enantiomer derived from racemic ketoconazole
Primary outcomes
What the sponsor says the trial is designed to measure.
- Normalization in Urinary Free Cortisol in Patients With Endogenous Cushing's Syndrome.Time frame: 6 months of maintenance phase therapy without a prior dose increase during that phase
Locations
42 sites in 15 countries. Site status is shown where the registry gives one.
UCLA School of Medicine
Los Angeles, California
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan Medical Center
Ann Arbor, Michigan
University of New Mexico HSC
Albuquerque, New Mexico
Memorial Sloan Kettering Cancer Center
New York, New York
Cleveland Clinic
Cleveland, Ohio
Oregon Health & Science University
Portland, Oregon
Allegheny Neuroendocrinology Center
Pittsburgh, Pennsylvania
University Hospitals Leuven Department of Endocrinology
Leuven, Belgium
University Specialized Hospital for Active Treatment in Endocrinology (USHATE)
Sofia, Bulgaria
St. Pauls Hospital/Vancouver General Hospital
Vancouver, British Columbia, Canada
Vseobecna fakultni nemocnice v Praze - III. Interni klinika VFN a 1. LF UK
Prague, Czechia
Aarhus University Hospital
Aarhus, Denmark
Rigshospitalet,Copenhagen University Hospital
Copenhagen, Denmark
Hôpital de la CONCEPTION, Service d'Endocrinologie, Diabète et Maladies Métaboliques
Marseille, France
Med Clinic I - University of Lueback
Lübeck, Germany
Bnail Zion Medical Center Institute of Endocrinology & Metabolism
Haifa, Israel
Institute of Endocrinology & Metabolism, Rabin Medical Center
Petah Tikva, Israel
Sourasky Medical Center, Endocrinology & Metabolism
Tel Aviv, Israel
Azienda Ospedaliera-Universitaria Ancona
Ancona, Italy
UOC di Endocrinologia, Dipartimento di Medicina Clinica e Sperimentale
Messina, Italy
Istituto Auxologico Italiano
Milan, Italy
University of Naples Federico II
Naples, Italy
SCDU Medicina Interna I Università di Torino Dipartimento di Scienze Cliniche e Biologiche
Orbassano, Italy
University of Padua
Padova, Italy
Institute of Medical Pathology
Roma, Italy
Azienda Ospedaliero - Universitaria Città della Salute e della Scienza di Torino
Torino, Italy
Policlinico GB Rossi
Verona, Italy
Leiden University, Leiden University Medical Center, Dept. of Endocrinology
Leiden, Netherlands
Erasmus MC, Dpt. Of Internal Medicine, Division of Endocrinology
Rotterdam, Netherlands
Instytut Centrum Zdrowia Matki Polki
Lodz, Poland
Terpa Sp.z.o.o
Lublin, Poland
Szpital Kliniczny im. Heliodora Swiecickiego
Poznan, Poland
Outpatient Clinic: Reuma Centrum
Warsaw, Poland
Samodzielny Publiczny Szpital Kliniczny Nr 1
Wroclaw, Poland
Clinical Center of Serbia
Belgrade, Serbia
Endocrinologia, Hospital Sant Pau,Universitat Autònoma de Barcelona
Barcelona, Spain
Hospital Universitario Reina Sofía
Córdoba, Spain
Hospital Universidad De La Ribera
Alzira, Valencia, Spain
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.